Optimizing T Cell-Based Therapy for Glioblastoma

Front Immunol. 2021 Aug 5:12:705580. doi: 10.3389/fimmu.2021.705580. eCollection 2021.

Abstract

Evading T cell surveillance is a hallmark of cancer. Patients with solid tissue malignancy, such as glioblastoma (GBM), have multiple forms of immune dysfunction, including defective T cell function. T cell dysfunction is exacerbated by standard treatment strategies such as steroids, chemotherapy, and radiation. Reinvigoration of T cell responses can be achieved by utilizing adoptively transferred T cells, including CAR T cells. However, these cells are at risk for depletion and dysfunction as well. This review will discuss adoptive T cell transfer strategies and methods to avoid T cell dysfunction for the treatment of brain cancer.

Keywords: CAR T cells; T cell dysfunction; adoptive T cell transfer; exhaustion; glioblastoma; glioma.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms* / immunology
  • Brain Neoplasms* / therapy
  • Glioblastoma* / immunology
  • Glioblastoma* / therapy
  • Humans
  • Immunotherapy, Adoptive*
  • Receptors, Chimeric Antigen* / immunology
  • Receptors, Chimeric Antigen* / therapeutic use

Substances

  • Receptors, Chimeric Antigen